<DOC>
	<DOCNO>NCT00819910</DOCNO>
	<brief_summary>The design study randomize , double blind trial , examine effect Rosiglitazone fast triglyceride ( TG ) , high-density lipoprotein ( HDL ) , low-density lipoprotein ( LDL ) , plasma concentration apolipoproteins A-I , A-II , C-III compare Fenofibrate placebo . This study also assess synergistic effect Rosiglitazone Fenofibrate parameter . Data study help clarify whether Rosiglitazone favorably impact plasma lipid lipoprotein concentration improve insulin sensitivity glycemic control , directly influence synthesis apolipoproteins responsible very-low-density lipoprotein ( VLDL ) HDL metabolism .</brief_summary>
	<brief_title>Rosiglitazone And Fenofibrate Additive Effects Lipids ( RAFAEL )</brief_title>
	<detailed_description>Treatment patient type 2 Diabetes Mellitus ( DM ) consist reduce hyperglycemia diet , exercise , oral drug therapy insulin ( 1 ) . The Thiazolidinedione ( TZDs ) , include Troglitazone ( withdrawn FDA ) , Rosiglitazone , Pioglitazone , correct hyperglycemia increase insulin sensitivity liver ( 2 , 3 ) skeletal muscle ( 4,5 ) . Although TZDs improve glycemic control type 2 diabetic subject , agent administer non-diabetic subject affect fast plasma glucose level . Nolan et al . ( 6 ) observe effect plasma glucose level non-diabetic subject treat Troglitazone 200 mg twice daily . Clinical trial use TZDs type 2 diabetic subject observe agent also favorably impact plasma lipid lipoprotein concentration . A recent study compare efficacy add Metformin ( 850 mg , twice daily ) Troglitazone ( 200 mg , twice daily ) Glyburide ( 10 mg , twice daily ) glycemic control type 2 diabetic patient ( n=22 ) , report 4 month treatment , Metformin induce significant change LDL-C , LDL size , HDL-C , Triglycerides Plasminogen Activator Inhibitor-1 ( PAI-1 ) , decrease C-reactive protein ( CRP ) 33 % . Interestingly , Troglitazone increase size LDL mean LDL-C level ( +10 % ) , decrease Triglyceride ( -22 % ) CRP ( -60 % ) concentration ( 7 ) . Following eight week treatment Rosiglitazone ( 4mg , twice daily ) 243 type 2 diabetic patient , mean HDL-C increase 6 % TG 2 % . The increase LDL-C concentration ( 9 % ) accompany shift small , dense LDL large , buoyant LDL 52 % treated subject . The shift LDL size occur independent significant Triglyceride reduction , contrast several study report increase LDL size significantly correlate decrease plasma concentration total low density lipoprotein ( VLDL ) Triglycerides ( 8-10 ) . The mechanism involve plasma lipid lipoprotein change induce TZDs remain unclear . It possible agent indirectly alter plasma lipid lipoprotein level indirectly improve insulin sensitivity glycemic control , directly influence lipoprotein synthesis and/or catabolism . In type 2 Diabetes Mellitus , hepatic synthesis Triglycerides increase peripheral catabolism decrease . The primary metabolic defect cause hypertriglyceridemia peripheral insensitivity action insulin , accompany hyperinsulinemia . The insulin insensitivity inhibit synthesis activity lipoprotein lipase consequently impair peripheral catabolism Triglyceride-rich lipoprotein ( VLDL Chylomicrons ) ( 11-12 ) . Since hepatocytes remain sensitive action insulin , hyperinsulinemia suppresses beta-oxidation shunt free fatty acid enter liver synthesis Triglycerides . Therefore , hepatic production Triglycerides ( i.e . VLDL ) increase time peripheral catabolism impair . The result hypertriglyceridemia reciprocal decease HDL-C concentration . By reduce insulin resistance plasma insulin level , TZDs would decrease hepatic Triglyceride production enhance peripheral catabolism Triglycerides , result plasma reduction reciprocal increase HDL-C level . Recently , recognize circulating level Triglyceride HDL-C influenced activity Peroxisome Proliferator Activator Receptors ( PPARs ) . PPARs constitute super family nuclear hormone receptor ligand-activated transcription factor . When activate , transmit signal intra-cellular lipid-soluble factor ( e.g . fatty acid , hormone , vitamin ) gene nucleus bind DNA specific response element ( 13 ) . Three distinct PPARs , term alpha , beta , gamma modulate intracellular lipid glucose metabolism control gene expression activate ( 14 ) . Specifically PPAR-alpha activate , gene expression synthesis ApoC-III , lipoprotein lipase , ApoA-I ApoA-II impact . ApoC-III specific inhibitor peripheral lipoprotein lipase compete ApoE space surface VLDL . Reduced amount ApoC-III result large representation ApoE VLDL particle , consequence , ApoE mediate hydrolysis Triglycerides enhance . Activation PPAR-alpha lead decrease production ApoC-III , turn result enhance clearance Triglycerides . Activation PPAR-alpha also increase synthesis lipoprotein lipase , increase Triglyceride catabolism . Gene expression synthesis ApoA-I ApoA-II also enhance activation PPAR-alpha , result increase HDL concentration . Fibric acid derivative ( Gemfibrozil Fenofibrate ) induce Triglyceride lower HDL-C augment property bind PPAR-alpha nuclear receptor . TZDs PPAR-gamma ligands stimulate gene expression GLUT1 GLUT4 ( cellular glucose transport protein ) lead increase insulin sensitivity target cell ( 15,16 ) . The three PPAR receptor possess degree structural homology . Therefore , TZDs high affinity PPAR-gamma , may also bind less degree PPAR-alpha beta . Saliel Olefsky ( 17 ) determine cell culture study Troglitazone activate three PPAR nuclear receptor . Lehmann et al . ( 18 ) observe vitro TZDs high affinity ligands PPAR-gamma yet also bind PPAR-alpha ( small degree ) . Binding PPAR-alpha would directly enhance catabolism Triglycerides ( i.e . reduce ApoC-III plasma concentration increase lipoprotein lipase activity ) increase HDL-C plasma concentration enhance expression lipoprotein lipase ApoA-I ApoA-II . Therefore , administration TZDs non-diabetic normoglycemic individual change plasma glucose concentration , bind PPAR-alpha would result decrease plasma concentration ApoC-III , increase ApoA-I ApoA-II , subsequent rise HDL-C reduction Triglyceride concentration . In recent animal study assess Rosiglitazone 's mode action lipid use male Sprague-Dawley rat , serum total , free HDL cholesterol concentration monitor . In rat give Rosiglitazone , serum Triglyceride level decrease dose-dependent manner , drop less 50 % control rat high dose test ( 5 mg/kg/d ) . Serum glucose concentration change Rosiglitazone treatment , agreement previous study show thiazolidinediones exert hypoglycemic action normoglycemic , non-diabetic rat . ( 18 )</detailed_description>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<criteria>Inclusion criterion : 1 . Fasting plasma glucose &lt; 100 mg/dl 2 . Fasting LDL &lt; 160 mg/dl Triglyceride &lt; 400 mg/dl . Exclusion criterion : 1 . Congestive heart failure 2 . Evidence renal impairment ( serum creatinine &gt; 1.4mg/dL ) 3 . Liver disease ( ALT and/or AST upper level normal ) 4 . Known diabetes mellitus impair fast glucose ( fast glucose ≥ 100mg/dL ) 5 . LDL ≥160mg/dL and/or triglyceride ≥400mg/dL 6 . Pregnant breast feed woman 7 . Prior history acute coronary syndrome , myocardial infarction revascularization procedure past 8 . Lifethreatening disease survival prognosis &lt; 3 year 9 . Inability take rosiglitazone and/or fenofibrate 10 . Already statin therapy statin therapy last 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Type 4 hyperlipidemia</keyword>
	<keyword>Rosiglitazone</keyword>
	<keyword>Fenofibrate</keyword>
</DOC>